SPEEDX
30.6.2021 10:21:09 CEST | Business Wire | Press release
SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005407/en/
“This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”
Throughout the past year of COVID-19, in response to the increased demand for molecular testing workflow solutions, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx complete the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary Plex PCR® technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.
“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology” said Maarten de Groot, MolGen CEO. “During the COVID pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About MolGen
MolGen is global total solution provider of innovative extraction DNA / RNA technology, system, products and kits for human and animal diagnostics, the agriculture and biotech industries which reduce hands-on time and increase productivity while maintaining high yields and reproducibility.
From sample to result, MolGen is challenging the status quo in molecular diagnostics by offering platform stand-alone systems and consumables. Highly customizable, MolGen’s portfolio offers the perfect workflow for our customers’ specific needs, being high-quality, adaptable and safe.
Due to travel restrictions Maarten de Groot, MolGen CEO and Colin Denver, SpeeDx CEO joined a virtual session to officially announce the collaboration that will combine Molgen liquid handling and purpose-built automation with SpeeDx COVID-19 diagnostic solutions - extending a full workflow offering to pathology laboratories.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005407/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Moody’s Corporation Elects Keith Demmings to Board of Directors12.8.2026 22:15:00 CEST | Press release
Moody’s Corporation (NYSE:MCO) today announced that Keith Demmings has been elected to the Company’s Board of Directors, effective November 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812902420/en/ Mr. Demmings, 54, currently serves as President and Chief Executive Officer of Assurant, Inc., a publicly traded company that safeguards and services connected devices, homes, automobiles, and commercial equipment in partnership with the world’s leading brands, a position he has held since January 2022. He has also served on Assurant’s Board of Directors since that time. Prior to his appointment as Chief Executive Officer, Mr. Demmings served as President of Assurant from 2021 to 2022, overseeing all operating segments, including Global Lifestyle and Global Housing. Earlier, he served as Executive Vice President and President, Global Lifestyle from 2016 to 2021, Executive Vice President and President, Global Markets
Lattice to Deliver Keynote at 2026 OCP Global Summit12.8.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that Lattice will deliver a keynote at the 2026 OCP Global Summit. Ford Tamer, President and CEO of Lattice Semiconductor, will take the stage with Sanjoy Maity, Senior Vice President, AMI Business Unit Leader, Lattice Semiconductor. Together, they will discuss the growing need for a common management and control model for AI and compute infrastructure, and how the OCP Community can work together to bring this vision to life with existing open technologies. The keynote will take place on Tuesday, Oct. 13, 2026, at 10 a.m. PT at the San Jose Convention Center (SJCC), South Hall, San Jose, California. The OCP Summit is the premier event uniting the most forward-thinking minds in open IT Ecosystem development. The Summit presents a unique platform for the OCP community from around the globe to share their insights, foster partnerships, and showcase cutting-edge advancements in op
BM3EAC Corp. 2026 Semi-Annual Report12.8.2026 17:51:00 CEST | Press release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2026 to 30 June 2026. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER The Company’s semi-annual report referenced in this announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. Forward-looking statements may
STL Selects Kinaxis Planning One to Strengthen Supply Chain Planning Across Global Operations12.8.2026 16:10:00 CEST | Press release
Deployment reflects Kinaxis' continued investment in India and expanding access through its growing partner ecosystem Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that STL (NSE: STLTECH), a leading optical and digital solutions company, has selected Kinaxis Planning One to strengthen its supply chain planning capabilities and improve decision-making speed across its global operations. The deployment reflects Kinaxis' continued commitment to the Indian market and represents another milestone in expanding customer access through its growing network of value-added reseller (VAR) partners, and its first customer win through the company's Google Marketplace mid-market initiative. "Manufacturers are under increasing pressure to respond to volatility with faster, more coordinated decisions," said Ray Curbelo, SVP, Global Partner Organization at Kinaxis. "This engagement with STL reflects both the growing demand for modern supply chain planning in Ind
Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development12.8.2026 16:00:00 CEST | Press release
Co-founder Andrés Vasquez Quintero assumes the CEO role while continuing as Chief Technology Officer, ensuring leadership continuity. Leadership transition positions Azalea Vision for clinical development of its smart contact lens platform, following selection for the EIC Accelerator. Co-founder Enrique Vega transitions to the Board of Directors, preserving founder continuity. Azalea Vision, a Belgian healthtech company, today announced that co-founder and CTO Andrés Vasquez Quintero will become Chief Executive Officer, effective immediately, while continuing as CTO. The transition marks the company’s next phase, advancing its smart contact lens platform into clinical development, following its selection for the European Innovation Council (EIC) Accelerator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812586109/en/ Andrés Vásquez Quintero, CEO & CTO of Azalea Vision As the inventor of Azalea Vision’s proprietary adapti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom